關(guān)鍵信息

    據(jù)評(píng)估，肺癌治療對(duì)指南的依從率為44%到52%,其中老年患者及存在合并癥的患者遵守率較低。依據(jù)指南治療的獲益和毒性均存在不確定性。較多的肺癌患者由于不符合臨床試驗(yàn)的納入標(biāo)準(zhǔn)而被排除（例如年齡太大、有合并癥或處于邊界性的表現(xiàn)狀態(tài)）。進(jìn)一步研究應(yīng)當(dāng)幫助明確指南中對(duì)于普通肺癌人群的合適治療方法，以增加其適用范圍。

    明確普通肺癌人群最佳治療方案的進(jìn)一步研究有助于將臨床試驗(yàn)轉(zhuǎn)化為臨床實(shí)踐。

    TAKE-HOME MESSAGE

    Adherence to treatment guidelines for lung cancer is estimated to range from 44% to 52%, with lower adherence for older patients and those with comorbidities. There is uncertainty regarding the benefit and toxicities of guideline treatments. Patients with lung cancer tend to have characteristics that may have been exclusion criteria for clinical trials （such as older age, comorbidities, or borderline performance status）。 Further research could help to define proper treatment of lung cancer to improve the applicability of the guidelines to the general population of lung cancer patients.

    Further research to define the best treatments in the general lung cancer population would help to translate evidence from clinical trials into clinical practice.